Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Completed · Phase 1

Conditions studied: Solid Tumors, Lymphoma

In brief

The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.

Key facts

Study ID

NCT01844583

Run by

Millennium Pharmaceuticals, Inc.

People needed

55

Starts

2013-06-25

Expected to finish

2016-09-06

Last updated by the study team

2019-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female participants 18 years or older
• Histologically or cytologically confirmed metastatic and/or advanced solid tumors or lymphomas
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Expected survival longer than 3 months from enrollment in the study
• Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse
• Male participants who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse

You may not qualify if…

• Treatment with any anticancer therapy or any investigational agents within 4 weeks before the first dose of alisertib
• Known hypersensitivity or intolerance to rifampin (for participants considered for the rifampin drug-drug interaction [DDI] group) or to esomeprazole (for participants considered for the esomeprazole DDI group)
• Recurrent nausea and/or vomiting within 14 days before the first dose of alisertib, and known gastrointestinal (GI) abnormality or GI procedure that could interfere with or modify the oral absorption or tolerance of alisertib
• Participants requiring treatment with clinically significant enzyme inducers within 14 days before the first dose of alisertib and/or requiring the use of these medications during the study
• A medical condition requiring use of pancreatic enzymes; or daily, chronic, or regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists
• Participants requiring systemic anticoagulation (excluding low-dose aspirin, or low-dose anticoagulation to maintain patency of venous access devices).
• Any cardiovascular condition
• Female participants who are lactating or have a positive serum pregnancy test
• Major surgery within the 14 days preceding the first dose of alisertib
• Life-threatening or uncontrolled medical illness unrelated to cancer
• Newly diagnosed or uncontrolled cancer-related central nervous system (CNS) disease
• Autologous stem cell transplant within 3 months
• Prior allogeneic bone marrow or other organ transplantation
• Other severe acute or chronic medical or psychiatric condition
• Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
• Please note there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Where it is running

• Study site — Sarasota, Florida, United States
• Study site — St Louis, Missouri, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Nashville, Tennessee, United States
• Study site — Dallas, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.